MicroRNA-125a-3p affects smooth muscle cell function in vascular stenosis

Area of Science:

• Vascular Biology
• Molecular Medicine
• MicroRNA Therapeutics

Background:

• MicroRNAs (miRNAs) are implicated in peripheral arterial disease (PAD).
• MicroRNA-125a-3p (miR-125a-3p) is downregulated in restenotic arteries.
• The precise role of miR-125a-3p in vascular stenosis remains unclear.

Purpose of the Study:

• To investigate the expression, regulatory mechanisms, and function of miR-125a-3p in vascular stenosis.
• To elucidate the role of miR-125a-3p in the development of vascular stenosis.

Main Methods:

• Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) to measure miR-125a-3p levels.
• Immunofluorescence and in situ hybridization for cellular localization.
• In vitro studies using vascular smooth muscle cells (VSMCs) transfected with miR-125a-3p mimics.
• Western blot and luciferase assays to identify targets.
• In vivo studies using balloon-injured rat carotid arteries.

Main Results:

• miR-125a-3p expression was significantly reduced in restenotic arteries compared to normal arteries.
• miR-125a-3p was primarily localized in the medial smooth muscle layer of arteries.
• Overexpression of miR-125a-3p inhibited VSMC proliferation and migration in vitro.
• Mitogen-activated protein kinase 1 (MAPK1) was identified as a direct target of miR-125a-3p.
• miR-125a-3p overexpression reduced neointimal hyperplasia in a rat model of vascular injury.

Conclusions:

• miR-125a-3p inhibits VSMC function and vascular stenosis by targeting MAPK1.
• This study reveals a novel molecular mechanism underlying PAD.
• Modulating miR-125a-3p levels presents a potential therapeutic strategy for PAD and other proliferative vascular diseases.